Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Meenu Kesarwani

Has grant

Senior staff scientist

Cincinnati Children's Hospital Medical Center

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States

Recent Grants

Grant: Close

Therapeutic targeting of High-Risk Per-B Acute Lymphoblastic Leukemmia

Open Date: 2018-06-01

Close Date: 2019-05-01

Articles (9)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (2)

Ross Levine

Member

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Tahir Latif

University of Cincinnati Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Meenu Kesarwani

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (9)

MOLECULAR PHARMACOLOGY AND DRUG RESISTANCE: MYELOID NEOPLASMS Novel BCR::ABL1 fusion alongside T315I reveals mechanism for dual ponatinib/asciminib resistance and proves sensitive to addition of axitinib

Momelotinib-mediated transcriptional reprogramming induces synthetic lethal interaction with calcineurin-NFAT signaling

Negative feedback regulation of nfkb, MAPK, and JAK-STAT drives adaptive resistance to gilteritinib in AML

Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformation

Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib

Targeting CDK16 Abrogates Growth-Factor Mediated TKI Resistance in AML

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML

MAPK-negative feedback regulation confers dependence to JAK2V617F signaling

DUSP1 Specific Protac Selectively Targets the JAK2 V617F Expressing Cells

Collaborators (2)

Ross Levine

Tahir Latif

Make your next move.